Click here for Part II & Part III

Acquiring and developing medicines that transform the lives of cancer patients and reduce the fear that follows a cancer diagnosis

Scott Applebaum is the president of Context Therapeutics, a biopharmaceutical company based in Philadelphia, PA. Founded in 215, Context is dedicated to discovering, acquiring, and developing medicines for patients with breast, prostate, ovarian, and other hormone-driven cancers. The company is currently focused on development of Apristor (Onapristone XR), an investigational Phase 2 drug that targets progesterone receptor positive (PR+) metastatic breast cancer.

EDWIN WARFIELD: You’re originally a lawyer. How did you transition into the pharma industry?

SCOTT APPLEBAUM: When I went to Stanford Law School, I really didn’t have a great idea of exactly what I wanted to do after law school. I wasn’t even sure where I wanted to end up, but I decided to come back to Philadelphia. My wife and I are both from Philadelphia and lifelong Philadelphians. We enjoyed it here, wanted to come back and start a family here, so I started to look for opportunities in Philadelphia. At the time, I started with Dechert, Price & Rhoads. Dechert is one of the largest firms in the world now; at the time, it was the largest firm in Philadelphia. I started as a tax associate, working in the area of tax, corporate tax, individual tax, employee benefits. I worked on a number of corporate transactions—M&A-type transactions—and did a variety of counseling. It was a great environment in which to learn. I worked with some great people there, some great mentors. But I also decided that I did not want to spend the rest of my life in a law firm. As much as I enjoyed it, I felt that there were probably more opportunities that would be a better fit for me in the corporate world, so I started to listen to and pursue opportunities outside of the law firm.

When I had the opportunity to join Bristol-Myers Squibb, that was something that really excited me, because I was able to use my expertise as a lawyer in part of an organization that I felt was really a dynamic industry and a great industry—one ultimately that’s focused on helping patients. When I started at Bristol-Myers Squibb, it was a very big difference from being at a law firm, where essentially you’re being rated on the quality of the work but also how many hours you bill. So, now, you’re working as part of a team that is ultimately being judged on the quality of the drugs you get to market and how well they do in the marketplace.

I worked at Bristol for about eight years and learned every aspect of the business I could. I had some great mentors at Bristol-Myers Squibb who gave me some stretch assignments and opportunities to work on some really important projects. My wife used to joke that when I was at cocktail parties and I was dispensing advice about high cholesterol and other things—she was like, “you’re not a doctor!” I said, “well, it’s true, but in narrow areas I think I know as much as anyone does.” And, we really did. The drugs that we worked on that I helped work with the regulatory filings, I helped worked with the promotion of those drugs—to really be effective, I had to learn as much about the drugs as anyone did. I had to really understand how doctors were going to prescribe it, the conditions that patients were living with, and how it was going to help them. I tried to learn as much as I could about the science. I am most definitely not a scientist, but I learned just enough probably to be dangerous.

I really enjoyed my time at Bristol-Myers Squibb, but it was a very large organization when I was there—about 50,000 employees. It had some ups and downs. Some of those downs for me personally were very big opportunities, because I got to work on a number of crises that the company was going through, and crises can be great learning experiences. I look back on that time very fondly because it really did give me a broad knowledge base and broad exposure to all different issues, both domestically and internationally.

Connect with Scott on LinkedIn

Sponsored by:

ABOUT NEWMARK KNIGHT FRANK

Newmark Knight Frank (NKF) is one of the world's leading commercial real estate advisory firms. Together with London-based partner Knight Frank and independently-owned offices, NKF's 15,000 professionals operate from more than 400 offices in established and emerging property markets on six continents.

With roots dating back to 1929, NKF's strong foundation makes it one of the most trusted names in commercial real estate. NKF's full-service platform comprises BGC's real estate services segment, offering commercial real estate tenants, landlords, investors and developers a wide range of services including leasing; capital markets services, including investment sales, debt placement, appraisal, and valuation services; commercial mortgage brokerage services; as well as corporate advisory services, consulting, project and development management, and property and corporate facilities management services. For further information, visit www.ngkf.com.

NKF is a part of BGC Partners, Inc., a leading global brokerage company servicing the financial and real estate markets. BGC's common stock trades on the NASDAQ Global Select Market under the ticker symbol (NASDAQ: BGCP). BGC also has an outstanding bond issuance of Senior Notes due June 15, 2042, which trade on the New York Stock Exchange under the symbol (NYSE: BGCA). BGC Partners is led by Chairman and Chief Executive Officer  Howard W. Lutnick. For more information, please visit www.bgcpartners.com.

Edwin Warfield, CEO of citybizlist, conducts the CEO Interviews.

If you're interested in reaching CEOs, please contact edwin.warfield@citybuzz.co

Connect on LinkedIn